Bagheri Mohammad Mehdi, Niknafs Pedram, Sabsevari Fatemeh, Torabi Mohammad Hosein, Bahman Bijari Bahareh, Noroozi Elahe, Mossavi Hamid
Afzalipour Medical Center, Kerman University of Medical Sciences, Kerman, IR Iran.
Iran J Pediatr. 2016 May 15;26(4):e3975. doi: 10.5812/ijp.3975. eCollection 2016 Aug.
Patent ductus arteriosus (PDA) is a common cause of morbidity. The aim of this study was to compare the efficacy of oral Acetaminophen and oral Ibuprofen for the closure of patent ductus arteriosus (PDA) in preterm infants.
This study demonstrated that, there was no significant difference between treatment of PDA with either oral Acetaminophen or oral Ibuprofen in preterm neonates.
This clinical trial, randomized study, enrolled 120 infants, with a gestational age of < 37 weeks, who were admitted in neonatal intensive care unit of Afzalipour hospital, Kerman, Iran, in 2014. PDA was confirmed echocardiographically. The trial was registered in Iranian registry of clinical trials (Reg. No. 25542). Sixty-seven infants received oral Acetaminophen (15mg/kg every six hours for three days) and 62 infants received Ibuprofen (an initial dose of 20 mg/kg, followed by 10 mg/kg at 24 and 48 hours). To evaluate the efficacy of the treatment, a second echocardiography was done after completing the treatment.
After the first course of the treatment, PDA closed in 55 (82.1 %) patients who received oral Acetaminophen vs. 47 (75.8 %) of those given oral Ibuprofen (P = 0.38). After the second course of treatment, PDA closed in 50 % of oral Acetaminophen group and 73.3% of oral Ibuprofen group (P = 0.21).
This study demonstrated that, there was no significant difference between treatment of PDA with either oral Acetaminophen or oral Ibuprofen in preterm neonates. Oral Ibuprofen can effectively close PDA but is unfortunately associated with some adverse effects limiting its utility thus we studied an alternative drug with similar efficacy and less adverse effects. This study has recommends Acetaminophen with minimal complications for the treatment of PDA in preterm neonates instead of Ibuprofen.
动脉导管未闭(PDA)是发病的常见原因。本研究的目的是比较口服对乙酰氨基酚和口服布洛芬对早产儿动脉导管未闭(PDA)闭合的疗效。
本研究表明,在早产儿中,口服对乙酰氨基酚或口服布洛芬治疗PDA之间没有显著差异。
这项临床试验为随机研究,纳入了2014年在伊朗克尔曼省阿夫扎利普尔医院新生儿重症监护病房收治的120例胎龄小于37周的婴儿。通过超声心动图确诊为PDA。该试验已在伊朗临床试验注册中心注册(注册号:25542)。67例婴儿接受口服对乙酰氨基酚(每6小时15mg/kg,共3天),62例婴儿接受布洛芬(初始剂量20mg/kg,在24小时和48小时后各追加10mg/kg)。为评估治疗效果,在完成治疗后进行了第二次超声心动图检查。
在第一个疗程后,接受口服对乙酰氨基酚的55例(82.1%)患者的PDA闭合,而接受口服布洛芬的患者中有47例(75.8%)闭合(P = 0.38)。在第二个疗程后,口服对乙酰氨基酚组中50%的患者PDA闭合,口服布洛芬组中73.3%的患者PDA闭合(P = 0.21)。
本研究表明,在早产儿中,口服对乙酰氨基酚或口服布洛芬治疗PDA之间没有显著差异。口服布洛芬可有效闭合PDA,但不幸的是会产生一些不良反应,限制了其应用,因此我们研究了一种疗效相似且不良反应较少的替代药物。本研究推荐使用并发症最少的对乙酰氨基酚来治疗早产儿的PDA,而非布洛芬。